Last reviewed · How we verify

Malignant tumor of head and/or neck — Treatment Landscape & Competitive Intelligence

Malignant tumor of head and/or neck (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Malignant tumor of head and/or neck, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Taxotere Docetaxel Sanofi Microtubule Inhibitor [EPC] Growth hormone-releasing hormone receptor 1996-01-01
Blenoxane BLEOMYCIN Bristol-Myers Squibb Cytoprotective Agent Aspartyl/asparaginyl beta-hydroxylase 1973-01-01
Trexall methotrexate Generic (originally Lederle Laboratories) Antifolate, DMARD Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4 1953-12-07
Xromi Xromi Nova Laboratories Limited Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Taxotere Taxotere Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor
Pembrolizuma Pembrolizuma Memorial Sloan Kettering Cancer Center Programmed cell death protein 1
Methotrexat Methotrexat Biocad Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4
Siklos Siklos Theravia Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Hydroxycarbamide Hydroxycarbamide University of Birmingham Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Hydroxycarbamid Hydroxycarbamid Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Biocad · 1 drug in Malignant tumor of head and/or neck
  2. Bristol-Myers Squibb · 1 drug in Malignant tumor of head and/or neck
  3. Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts · 1 drug in Malignant tumor of head and/or neck
  4. Fudan University · 1 drug in Malignant tumor of head and/or neck
  5. Generic (originally Lederle Laboratories) · 1 drug in Malignant tumor of head and/or neck
  6. Memorial Sloan Kettering Cancer Center · 1 drug in Malignant tumor of head and/or neck
  7. Nova Laboratories Limited · 1 drug in Malignant tumor of head and/or neck
  8. Sanofi · 1 drug in Malignant tumor of head and/or neck
  9. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 1 drug in Malignant tumor of head and/or neck
  10. Theravia · 1 drug in Malignant tumor of head and/or neck
  11. University of Birmingham · 1 drug in Malignant tumor of head and/or neck

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Malignant tumor of head and/or neck:

Cite this brief

Drug Landscape (2026). Malignant tumor of head and/or neck — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malignant-tumor-of-head-and-or-neck. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing